Will AstraZeneca plc Take The Hatchet To Its Dividend?

Royston Wild explains why AstraZeneca plc (LON: AZN) may have to slash shareholder payments.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why I believe AstraZeneca (LSE: AZN) (NYSE: AZN.US) could be in line for a painful dividend cut.astrazeneca2

The prescription for payout problems

Thanks to a prolonged period of earnings growth, pharma giant AstraZeneca had forged a reputation as a reliable provider of year-on-year dividend growth. But as the effect of patent expirations have hammered revenues from its previously enviable suite of market-leading drugs, the firm’s earnings — and with it dividend — record has dropped off considerably.

Indeed, two years of earnings falls have forced the business to keep the total payment on hold at 280 US cents per share. And with declines to the tune of 15% and 7% pencilled in for 2014 and 2015 respectively, City analysts expect the London firm to bite the bullet and reduce the dividend to around 270 cents for both of the next two years.

Even though AstraZeneca has kept dividends frozen since 2011, yields have remained far above the British blue-chip average. And current projections suggest that this is set to continue, with prospective payments for 2014 and 2015 carrying yields of 3.9%, beating a forward average of 3.5% for the entire FTSE 100.

… while murky profits picture undermines long-term growth

Still, AstraZeneca’s expected decision to cut the dividend this year has seen the yield creep closer to that of its big-cap rivals.

And with forecasts through to the end of next year boasting meagre dividend coverage — payouts are covered just 1.6 times and 1.5 times by earnings in 2014 and 2015, well below the safety threshold of 2 times or above — the drugs giant may be forced to take the red marker to current dividend expectations.

The business confirmed in July that it aims to raise or at least maintain the full-year payout. However, it admitted that “some earnings fluctuations are to be expected as the… revenue base transitions through this period of exclusivity losses and new product launches,” a worrying portent considering its R&D team is still playing catch-up with its industry rivals.

AstraZeneca elected to pay out an interim dividend of 90 cents for the first half of the year, which it said was consistent with its target of paying out around a third of 2013’s total payout. But should the firm’s near-term sales forecasts sour and its product pipeline begin to stutter, the company may struggle to get close to last year’s sum in 2014.

Allied with the astronomical costs attributed to the business of pharmaceuticals research, and the cost of AstraZeneca’s establishment of a pan-global lab network — net debt rung in at a vast $4bn during January-June — dividends may come under pressure not just now but well into the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »